ADVERTISEMENT

Trends in Troponin-Only Testing for AMI in Academic Teaching Hospitals and the Impact of Choosing Wisely®

Journal of Hospital Medicine 12(12). 2017 December;957-962. Published online first September 20, 2017 | 10.12788/jhm.2846

BACKGROUND: Identifying hospitals that are both early and consistent adopters of high-value care can help shed light on the culture and practices at those institutions that are necessary to promote high-value care nationwide. The use of troponin to diagnose acute myocardial infarction (AMI), and not to test for myoglobin or creatine kinase-MB (CK-MB), is a high-value recommendation of the Choosing Wisely® campaign.

OBJECTIVE: To examine the variation in cardiac biomarker testing and the effect of the Choosing Wisely® troponin-only recommendation for the diagnosis of AMI.

DESIGN: A retrospective observational study using administrative ordering data from Vizient’s Clinical Database/Resource Manager.

SETTING: Ninety-one academic medical centers from the fourth quarter of 2013 through the third quarter of 2016.

PATIENTS: Hospitalized patients with a principal discharge diagnosis of AMI.

INTERVENTION: The Choosing Wisely® recommendation to order troponin-only testing to diagnose AMI was released during the first quarter of 2015.

RESULTS: In 19 hospitals, troponin-only testing was consistently ordered to diagnose AMI before the Choosing Wisely® recommendation and throughout the study period. In 34 hospitals, both troponin and myoglobin/CK-MB were ordered to diagnose AMI even after the Choosing Wisely® recommendation. In 26 hospitals with low rates of troponin-only testing before the Choosing Wisely® recommendation, the release of the recommendation was associated with a statistically significant increase in the rate of troponin-only testing to diagnose AMI.

CONCLUSION: In institutions with low rates of troponin-only testing prior to the Choosing Wisely® recommendation, the recommendation was associated with a significant increase in the rate of troponin-only testing.

© 2017 Society of Hospital Medicine

The Effect of Choosing Wisely® on Troponin-Only Testing

While in many institutions the rates of troponin-only testing were increasing before the Choosing Wisely® recommendation was released in 2015, the release of the recommendation was associated with a significant increase in the rate of troponin-only testing in the institutions that were in the bottom tertile of troponin-only testing prior to the release of the recommendation but moved to the top tertile after the release of the recommendation (n = 5). The slope percentage of the rate of change of the 5 hospitals that went from the bottom tertile to the top tertile after the release of the Choosing Wisely® recommendation was 5.7%. Additionally, the Choosing Wisely® recommendation was associated with an accelerated rate of troponin-only testing in hospitals moving from the bottom tertile before the release of the recommendation to the middle tertile after the recommendation (n = 15; slope = 3.2%) and in hospitals moving from the middle tertile before the release of the recommendation to the top tertile after (n = 6; slope = 2.4%) (Figure 2). For all of these hospitals (n = 26), the increased rate of troponin-only testing in the study quarter after the Choosing Wisely® recommendation was statistically significantly higher and different from the rate of troponin-only testing in all other study quarters, except for the period between 2014 quarter 3 and quarter 4 (P = 0.08), the period between 2015 quarter 2 and quarter 3 (P = 0.18), and 2015 quarter 3 and quarter 4 (P = 0.06), where the effect did not quite reach statistical significance (Figure 3).

DISCUSSION

In a broad sample of academic teaching hospitals, there was an overall increase in the rate of troponin-only testing starting from the fourth quarter of 2013 through the third quarter of 2016. However, there was wide variation in the adoption of troponin-only testing for AMI across institutions. Our study identified several high-performing hospitals where the rate of troponin-only testing was high prior to and after the Choosing Wisely® troponin-only recommendation. Additionally, we identified several poor-performing hospitals, which even after the release of the Choosing Wisely® recommendation continue to order both troponin and myoglobin/CK-MB tests for the diagnosis of AMI. Lastly, we identified several hospitals in which the release of the Choosing Wisely® recommendation was associated with a significant increase in the rate of troponin-only testing for the diagnosis of AMI. 
The high-performing hospitals in our sample that were in the top tertile of troponin-only testing throughout the study period are “early adopters,” having already instituted troponin-only testing before the release of the Choosing Wisely® troponin-only recommendation. These hospitals vary in size, geographic region of the country, volume of AMI patients cared for, whether AMI patients are cared for by a cardiologist or other provider, and quality rating. Interestingly, in these hospitals, AMI patients admitted under the care of a cardiologist had higher rates of troponin-only testing than when admitted under another physician type. This is perhaps not surprising given that cardiologists would be the most likely to be aware of the data supporting troponin-only testing prior to the Choosing Wisely® recommendation and the most likely to institute interventions to promote troponin-only testing and disseminate this knowledge across their institution. These institutions and their practice of troponin-only testing before the Choosing Wisely® recommendation represent the idea of positive deviance,10 whereby they had identified troponin-only testing as a superior strategy and instituted successful initiatives to reduce the use of unnecessary myoglobin and CK-MB testing before their peer hospitals and the release of the Choosing Wisely® recommendation. Further efforts to explore and understand the additional factors that define the hospitals that had high rates of troponin-only testing prior to the Choosing Wisely® recommendation may be helpful to understanding the necessary culture and institutional factors that can promote high-value care.

In the hospitals that demonstrated increasing adoption of troponin-only testing, there are several interesting patterns. First, among these hospitals, smaller hospitals tended to have higher overall rates of troponin-only testing per 100 patients than larger hospitals. Additionally, the hospitals with the highest rates were located in the Midwest region. These hospitals may be learning from and following the high-performing institutions observed in our data that are also located in the Midwest. Additionally, among the hospitals that significantly increased their rate of troponin-only testing, we see that the Choosing Wisely® recommendation appeared to facilitate accelerated adoption of troponin-only testing. In these institutions, it is likely that the impact of Choosing Wisely® was significant because there was attention to high-value care and already an existing movement underway to institute such high-value practices. For example, natural champions, leadership, infrastructure, and a supportive culture may all be prerequisites for Choosing Wisely® recommendations to become institutionally adopted.

Lastly, in the hospitals that have continued to order myoglobin and CK-MB, future work is needed to understand and overcome barriers to adopting high-value care practices.

There are several limitations to this study. First, because this was an observational study, we cannot prove a causal relationship between the Choosing Wisely® recommendation and the increased rates of troponin-only testing. Additionally, the Vizient CDB/RM contains reporting data for a limited number of academic medical centers only, and therefore, these results may not represent practices at nonacademic or even other academic medical centers. Our study only included patients with a principal discharge diagnosis of AMI because the Choosing Wisely® recommendation to order troponin-only is specific for diagnosing patients with AMI. However, it is possible that the Choosing Wisely® recommendation also has affected provider ordering in patients with diagnoses such as chest pain or angina, and these affects would not be captured in our study. Lastly, because instituting high-value care practices take time, our follow-up time may not have been long enough to capture improvement in troponin-only testing at institutions responding to and attempting to adhere to the Choosing Wisely® recommendation to order troponin-only testing for patients with AMI.